Recent Updates
Recently added Catalysts
IQV Positive Sentiment

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group

Monday, August 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: IQVIA has been recognized as the top pharmaceutical technology provider by Everest Group for 2026, achieving a remarkable score of 96.8 out of 100. This ranking highlights IQVIA's extensive technology offerings and leadership in the clinical research and healthcare intelligence sectors. The accolade underscores the company's commitment to innovation and excellence in the life sciences industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • IQVIA ranked No. 1 in Everest Group's report.
  • Achieved a high score of 96.8 out of 100.
  • Recognition reflects IQVIA's strong technology capabilities.

Full Press Release Details

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA’s broad technology cover

Frequently Asked Questions

What ranking did IQVIA achieve in 2026?

IQVIA was ranked No. 1 in Everest Group's report for pharmaceutical technology providers.

What score did IQVIA receive from Everest Group?

IQVIA received a score of 96.8 out of 100.

What does the ranking recognize about IQVIA?

The ranking recognizes IQVIA's broad technology capabilities in the life sciences sector.

ShareAdd on Google
Tags: IQV Viatris Investor Conferences Healthcare IQVIA pharmaceutical technology Everest Group clinical research healthcare intelligence
Last updated: Aug 17, 2026

Biotech snapshot

Cash runway
$2103M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Humira in Prefilled SyringePhase 3
Moderate Chronic Plaque Psoriasis →